Canada

FSD Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

Lead Product(s): Palmitoylethanolamide

Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

FSD Pharma announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201.

Appili Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

First clinical study to examine the use of favipiravir for COVID-19 outbreak control; National Institute on Ageing estimates over 80 per cent of COVID-19 deaths in Canada are occurring at long-term care facilities.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Arch Biopartners Expands Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

Lead Product(s): LSALT peptide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 19, 2020

Details:

The expansion of primary endpoint of the Phase II human trial for LSALT reflects recent global data from COVID-19 patients that shows the SARS-CoV-2 virus results in damage to organs besides the lungs and Metablok’s potential to prevent inflammation injury in multiple organs.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

Lead Product(s): LSALT peptide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

Details:

The Phase II trial will be a multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Algernon Re-purposes Ifenprodil Drug Against COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

Phase 2 trial is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Algernon Pharma receives South Korean regulatory approval to begin phase 2 COVID-19 study of Ifenprodil

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2020

Details:

Algernon has received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval for a Phase 2 COVID-19 clinical study of NP-120 (Ifenprodil).

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 02, 2020

Details:

The protocol for a planned physician initiated phase 2 clinical study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea has been finalized.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

FSD Pharma

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

Appili Therapeutics

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

Arch Biopartners

Arch Biopartners Expands Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

Arch Biopartners

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

Algernon Pharmaceuticals

Algernon Re-purposes Ifenprodil Drug Against COVID-19

Algernon Pharmaceuticals

Algernon Pharma receives South Korean regulatory approval to begin phase 2 COVID-19 study of Ifenprodil

Algernon Pharmaceuticals

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19